Skip to main content

Table 1 Persistent diabetic macular edema through 3 and 6 months

From: Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients

Patients with persistent DME

Month 3 (week 12)

(n/N, %)

Month 6 (week 24)

(n/N; %)

Aflibercept (Eylea®)

95/187 (50.80%)

60/190 (31.58%)

Ranibizumab (Lucentis®)

91/171 (53.22%)

73/176 (41.48%)

Bevacizumab (Avastin®)

129/177 (72.88%)

118/180 (65.56%)

  1. At 24 weeks, p < 0.001 for aflibercept vs bevacizumab, p = 0.05 for aflibercept vs ranibizumab and p < 0.001 for ranibizumab vs bevacizumab
  2. Source: Bressler NM, et al. JAMA Ophthalmol. 2018;136(3):257–69 [6].